Skip to main content
  • Book
  • © 2017

Chemotherapy for Leukemia

Novel Drugs and Treatment

Editors:

(view affiliations)
  • Elucidates the latest progress in chemotherapy for leukemia and related diseases

  • Presents prospective results of basic and preclinical studies for leukemia

  • Maximizes reader insight into modern treatment methodology for leukemia

Buying options

eBook
USD 129.00
Price excludes VAT (USA)
  • ISBN: 978-981-10-3332-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD 169.99
Price excludes VAT (USA)
Hardcover Book
USD 169.99
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (20 chapters)

  1. Front Matter

    Pages i-viii
  2. An Overview

    • Takanori Ueda
    Pages 1-7
  3. Bcr-Abl Tyrosine Kinase Inhibitors (TKIs)

    1. Front Matter

      Pages 9-9
    2. Imatinib: Basic Results

      • Fujiko Tsukahara, Yoshiro Maru
      Pages 11-31
  4. Signaling Inhibitors

    1. Front Matter

      Pages 165-165
    2. FLT3 Inhibitors

      • Hitoshi Kiyoi
      Pages 167-179
  5. New Chemotherapeutic Agents Including Antimetabolite

    1. Front Matter

      Pages 239-239
    2. Nelarabine

      • Takahiro Yamauchi, Takanori Ueda
      Pages 241-250

About this book

This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells.

This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.

Keywords

  • Acute promyelocytic leukemia
  • Chronic myeloid leukemia
  • Molecular targeted agent
  • antimetabolite analogues
  • chemokine receptor 4
  • epigenetic regulator
  • leukemic stem cells
  • signaling inhibitors

Editors and Affiliations

  • University of Fukui, Fukui, Japan

    Takanori Ueda

About the editor

Takanori Ueda

Vice-President, University of Fukui Faculty of Medical Sciences,

3-9-1 Bunkyo, Fukui 910-8507, Japan

Bibliographic Information

  • Book Title: Chemotherapy for Leukemia

  • Book Subtitle: Novel Drugs and Treatment

  • Editors: Takanori Ueda

  • DOI: https://doi.org/10.1007/978-981-10-3332-2

  • Publisher: Springer Singapore

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Nature Singapore Pte Ltd. 2017

  • Hardcover ISBN: 978-981-10-3330-8

  • Softcover ISBN: 978-981-10-9844-4

  • eBook ISBN: 978-981-10-3332-2

  • Edition Number: 1

  • Number of Pages: VIII, 361

  • Number of Illustrations: 31 b/w illustrations, 51 illustrations in colour

  • Topics: Oncology, Hematology

  • Industry Sectors: Biotechnology, Health & Hospitals, Pharma

Buying options

eBook
USD 129.00
Price excludes VAT (USA)
  • ISBN: 978-981-10-3332-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD 169.99
Price excludes VAT (USA)
Hardcover Book
USD 169.99
Price excludes VAT (USA)